화학요법 유발성 빈혈 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 질환 유형별, 치료 유형별, 약제 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Chemotherapy-Induced Anemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Treatment Type, By Drug Type, By End User, By Region and Competition, 2020-2030F
상품코드:1668179
리서치사:TechSci Research
발행일:2025년 02월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 화학요법 유발성 빈혈(CIA) 시장 규모는 2024년에 28억 6,000만 달러에 달하며, 2030년에는 43억 1,000만 달러에 달할 것으로 예측되며, 예측 기간 중 CAGR은 7.02%로 추이할 것으로 예측됩니다.
화학요법 유발성 빈혈 시장은 암 환자의 주요 치료법인 화학요법으로 인해 암 치료 분야에서 중요한 초점이 되고 있습니다. 화학요법의 사용이 계속 증가함에 따라 화학요법 유발성 빈혈의 유병률도 동시에 증가하고 있습니다. 이 증상은 암 환자의 삶의 질에 영향을 미칠 뿐만 아니라 제약회사 및 의료 서비스 프로바이더에게 큰 비즈니스 기회를 제공합니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
28억 6,000만 달러
시장 규모 : 2030년
43억 1,000만 달러
CAGR: 2025-2030년
7.02%
급성장 부문
병원·클리닉
최대 시장
북미
화학요법 유발성 빈혈은 화학요법의 흔한 부작용으로, 화학요법 약물이 골수의 적혈구 생성 능력을 손상시켜 혈액내 헤모글로빈 농도를 감소시켜 발생합니다. 이 상태는 피로, 쇠약감, 호흡곤란 등의 증상을 유발하고 추가 암 치료에 대한 내성을 떨어뜨립니다. 그 결과, CIA의 관리는 암 치료의 중요한 측면이 되어 효과적인 치료에 대한 수요가 증가하고 있습니다.
CIA는 광범위한 암 환자에게 영향을 미치며, 미국 암 협회의 보고에 따르면 화학요법을 받는 암 환자의 30-90%가 정도의 차이는 있지만 빈혈을 경험하고 있으며, CIA 치료에는 적혈구 조혈 자극제(ESA), 철분 보충제, 수혈, 새로운 치료법 등이 있습니다. 에리스로포이에틴 자극제 및 달베포에틴 알파를 포함한 ESA는 일반적으로 CIA를 관리하기 위해 사용되어 왔으나, 안전성 문제 및 규제 변경으로 인해 사용량이 감소하고 있습니다. 등 주요 제약회사들이 이 질환에 대한 치료제를 개발 및 판매하고 있습니다.
CIA 시장은 역동적이며, 과제와 기회를 모두 가져다주는 역동적인 시장입니다. 규제와 상환 문제가 큰 걸림돌로 작용하고 있지만, 지속적인 연구, 환자 중심 치료, 업계와의 협력, 시장 확대는 유망한 미래를 가져다 줄 것입니다. 헬스케어 업계가 암 환자의 행복을 최우선 과제로 삼고 있는 가운데, CIA 관리의 발전은 화학요법을 받는 환자의 삶의 질을 향상시키는 데 매우 중요합니다. 제약회사와 의료 서비스 프로바이더는 증가하는 환자 집단의 요구를 충족시키기 위해 민첩하고 혁신적이어야 합니다.
The Global Chemotherapy-Induced Anemia (CIA) Market was valued at USD 2.86 billion in 2024 and is projected to reach USD 4.31 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.02% during the forecast period. The market for chemotherapy-induced anemia has become a significant focus within the oncology sector, with chemotherapy being a primary treatment for cancer patients. As chemotherapy use continues to rise, the prevalence of chemotherapy-induced anemia has concurrently increased. This condition not only impacts cancer patients' quality of life but also presents substantial business opportunities for pharmaceutical companies and healthcare providers.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.86 Billion
Market Size 2030
USD 4.31 Billion
CAGR 2025-2030
7.02%
Fastest Growing Segment
Hospitals & Clinics
Largest Market
North America
Chemotherapy-induced anemia is a common side effect of chemotherapy, occurring when chemotherapy drugs impair the bone marrow's ability to produce red blood cells, thereby reducing hemoglobin levels in the blood. This condition can result in symptoms such as fatigue, weakness, shortness of breath, and a reduced tolerance for further cancer treatments. As a result, the management of CIA has become a key aspect of cancer care, leading to increased demand for effective treatments.
CIA affects a wide range of cancer patients, with the American Cancer Society reporting that 30-90% of cancer patients undergoing chemotherapy experience varying degrees of anemia. Treatments for CIA include erythropoiesis-stimulating agents (ESAs), iron supplements, blood transfusions, and emerging therapies. ESAs, including erythropoietin-stimulating agents and darbepoetin alfa, have been commonly used to manage the condition, although safety concerns and regulatory changes have impacted their usage. Key players in the CIA market include major pharmaceutical companies such as Amgen, Johnson & Johnson, and Roche, which are developing and marketing treatments for this condition.
The CIA market is dynamic, presenting both challenges and opportunities. Regulatory concerns and reimbursement issues pose significant hurdles, but ongoing research, patient-centered care, industry collaboration, and market expansion offer a promising future. As the healthcare industry continues to prioritize cancer patient well-being, advancements in CIA management will be crucial to improving the quality of life for those undergoing chemotherapy. Pharmaceutical companies and healthcare providers must remain agile and innovative to meet the needs of this growing patient population.
Key Market Drivers
Increasing Incidence of Cancer: The global incidence of cancer is a significant driver of the chemotherapy-induced anemia market. As cancer cases continue to rise, so does the demand for effective treatments, including chemotherapy. Despite its effectiveness, chemotherapy is associated with side effects such as CIA, which is gaining increased attention. The rising cancer incidence is prompting research, innovation, and the development of therapies to manage this condition.
According to the World Cancer Research Fund, there were 19,976,499 cancer cases worldwide in 2022, including non-melanoma skin cancer. Excluding non-melanoma skin cancer, the number of cases was 18,741,966, with nearly equal distribution between men (9,566,825 cases) and women (9,175,141 cases).
Key Market Challenges
Regulatory Barriers: Regulatory hurdles pose significant challenges for companies in the CIA market. Navigating the complex regulatory environment requires substantial resources and time. Regulatory agencies, including the FDA and EMA, require extensive preclinical and clinical data to evaluate the safety and efficacy of new therapies. This process is often lengthy and costly, delaying time to market and increasing financial strain for companies. Regulatory requirements also vary across regions, further complicating international market expansion. Smaller firms, in particular, face challenges competing with larger, more established companies with greater resources and experience in managing regulatory processes.
Key Market Trends
Rising Awareness and Early Diagnosis of Chemotherapy-Induced Anemia: Increasing awareness and early diagnosis of CIA is a major driver of the global market. As cancer incidence grows and treatment regimens become more complex, there is greater recognition of the impact of chemotherapy-induced anemia on patients' quality of life. Previously underdiagnosed or underappreciated, CIA is now receiving more attention from healthcare professionals, leading to an increased demand for treatment options.
Key Market Players
Dr. Reddy's Laboratories Ltd.
Pfizer Inc.
Panacea Biotec Limited
SBI Pharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
PharmaEssentia Corp.
PhytoHealth Corp
UBI Pharma Inc.
Amgen Inc.
Astellas Pharma Inc.
Report Scope
This report segments the Global Chemotherapy-Induced Anemia Market as follows:
By Disease Type:
Mild Anemia
Moderate Anemia
Severe Anemia
By Treatment Type:
RBC Transfusions
Erythropoiesis-Stimulating Agents (ESAs)
Iron Supplementation
By Drug Type:
Epogen Injection
Procrit Injection
Androxy Oral
Aranesp Injection
Epoetin Alfa Injection
Others
By End User:
Hospitals & Clinics
Ambulatory Care Centers
Others
By Region:
North America: United States, Canada, Mexico
Europe: France, United Kingdom, Italy, Germany, Spain
Asia-Pacific: China, India, Japan, Australia, South Korea
South America: Brazil, Argentina, Colombia
Middle East & Africa: South Africa, Saudi Arabia, UAE
Competitive Landscape
This section provides a detailed analysis of the major companies operating in the Chemotherapy-Induced Anemia Market.
Available Customizations
The Global Chemotherapy-Induced Anemia market report offers the following customizations tailored to the needs of specific companies:
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Chemotherapy-Induced Anemia Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Mild Anemia, Moderate Anemia, Severe Anemia)
5.2.2. By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation)
5.2.3. By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others)
5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Chemotherapy-Induced Anemia Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Treatment Type
6.2.3. By Drug Type
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Chemotherapy-Induced Anemia Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Treatment Type
6.3.1.2.3. By Drug Type
6.3.1.2.4. By End User
6.3.2. Canada Chemotherapy-Induced Anemia Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Treatment Type
6.3.2.2.3. By Drug Type
6.3.2.2.4. By End User
6.3.3. Mexico Chemotherapy-Induced Anemia Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Treatment Type
6.3.3.2.3. By Drug Type
6.3.3.2.4. By End User
7. Europe Chemotherapy-Induced Anemia Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Treatment Type
7.2.3. By Drug Type
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Chemotherapy-Induced Anemia Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Treatment Type
7.3.1.2.3. By Drug Type
7.3.1.2.4. By End User
7.3.2. United Kingdom Chemotherapy-Induced Anemia Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Treatment Type
7.3.2.2.3. By Drug Type
7.3.2.2.4. By End User
7.3.3. Italy Chemotherapy-Induced Anemia Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Treatment Type
7.3.3.2.3. By Drug Type
7.3.3.2.4. By End User
7.3.4. France Chemotherapy-Induced Anemia Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Treatment Type
7.3.4.2.3. By Drug Type
7.3.4.2.4. By End User
7.3.5. Spain Chemotherapy-Induced Anemia Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Treatment Type
7.3.5.2.3. By Drug Type
7.3.5.2.4. By End User
8. Asia-Pacific Chemotherapy-Induced Anemia Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Treatment Type
8.2.3. By Drug Type
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Chemotherapy-Induced Anemia Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Treatment Type
8.3.1.2.3. By Drug Type
8.3.1.2.4. By End User
8.3.2. India Chemotherapy-Induced Anemia Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By Drug Type
8.3.2.2.4. By End User
8.3.3. Japan Chemotherapy-Induced Anemia Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Treatment Type
8.3.3.2.3. By Drug Type
8.3.3.2.4. By End User
8.3.4. South Korea Chemotherapy-Induced Anemia Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Treatment Type
8.3.4.2.3. By Drug Type
8.3.4.2.4. By End User
8.3.5. Australia Chemotherapy-Induced Anemia Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Treatment Type
8.3.5.2.3. By Drug Type
8.3.5.2.4. By End User
9. South America Chemotherapy-Induced Anemia Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Treatment Type
9.2.3. By Drug Type
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Chemotherapy-Induced Anemia Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Treatment Type
9.3.1.2.3. By Drug Type
9.3.1.2.4. By End User
9.3.2. Argentina Chemotherapy-Induced Anemia Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By Drug Type
9.3.2.2.4. By End User
9.3.3. Colombia Chemotherapy-Induced Anemia Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Treatment Type
9.3.3.2.3. By Drug Type
9.3.3.2.4. By End User
10. Middle East and Africa Chemotherapy-Induced Anemia Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Treatment Type
10.2.3. By Drug Type
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Chemotherapy-Induced Anemia Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Treatment Type
10.3.1.2.3. By Drug Type
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Chemotherapy-Induced Anemia Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Treatment Type
10.3.2.2.3. By Drug Type
10.3.2.2.4. By End User
10.3.3. UAE Chemotherapy-Induced Anemia Market Outlook
